期刊文献+

生物人工肝中细胞材料的研究进展

原文传递
导出
摘要 急性肝功能衰竭是一类死亡率极高的综合症候群。近年来,虽然临床治疗手段不断改进,死亡率仍然高达50%~80%,暴发性肝功能衰竭者甚至可达90%以上。目前,肝移植是治疗肝功能衰竭最为有效的手段,但由于供肝短缺使众多病人失去移植的机会,或由于等待时间过久造成移植前病人全身状况过差给手术本身带来极大风险。生物人工肝(bioartificial liver,BAL)是近20年来发展起来的新型人工肝支持系统,其基本原理是将体外培养增殖的肝细胞置于生物反应器中,使病人血清通过反应器内的纤维半透膜与培养的肝细胞进行物质交换,
出处 《中华肝胆外科杂志》 CAS CSCD 2008年第8期590-592,共3页 Chinese Journal of Hepatobiliary Surgery
  • 相关文献

参考文献2

二级参考文献19

  • 1[1]Emond JC, Whitington PF, Thistlethwaite JR, Cherqui D, Alonso EA, Woodle IS, Vogelbach P, Busse-Henry SM, Zucker AR,Broelsch CE. Transplantation of two patients with one liver. Ann Surg 1990; 212:14-22
  • 2[2]Shaw BW. More questions than answers. Liver Transplant Surg 1995; 1:404-407
  • 3[3]Everhart JE, Lombardero M, Detre KM, Zetterman RK, Wiesner RH, Lake JR, Hoofnagle JH. Increased waiting time for liver transplantation results in higher mortality. Transplantation 1997; 64:1300-1306
  • 4[4]Bilsuttil W, Klintmalm B. Transplantation of the liver Philadelphia. W. B. Saunders Company 1996:861
  • 5[5]Emond JC, Whitington PF, Thistlethwaite JR, Alonso EM,Broelsch CE. Reduced-size orthotopic liver transplantation: use in the management of children with chronic liver disease.Hepatology 1989; 10:867-872
  • 6[6]Friedman AL. Why bioartificial liver support remains the holy grail. ASAIO 1998; 44:241-243
  • 7[7]Kamihira M, Yamada K, Hamamoto R, Iijima S. Speroid formation of hepatocytes using synthetic polymer. Ann NY Acad Sci 1997; 831:398-407
  • 8[8]Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs 1994; 18:390-396
  • 9[9]Dixit V. Development of a bioartificial liver using isolated hepatocytes. Artif Organs 1994; 18:371-384
  • 10[10]Hui T, Rozga J, Demetriou AA. Bioartificial liver support. J Hepatobiliary Surg 2001; 8:1-15

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部